/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies
Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies

Research To Practice | Oncology Videos · Oct 5, 2026

Dr. Elizabeth Budde explains using CD20xCD3 bispecific antibodies in DLBCL, highlighting outpatient safety, novel combos, and re-biopsy.

Mandate Re-Biopsies Post-CAR-T or Bispecific Progression to Detect CD19 and CD20 Antigen Loss

Target antigen loss or modulation on tumor surfaces is a frequent mechanism of resistance following CD19 CAR-T or CD20 bispecific antibody failure. Dr. Budde highlights that treating relapsed patients with further targeted therapy without a biopsy frequently leads to treatment failure, as tumors often become CD19- or CD20-negative. Re-biopsying is vital to confirm target presence before initiating next-line therapies.

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies thumbnail

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies

Research To Practice | Oncology Videos·a month ago

Steroid Prophylaxis Does Not Diminish Activated T-Cell Efficacy During Bispecific Antibody Therapy

Clinicians often worry that steroid premedication or mitigation blunts the cytotoxic efficacy of bispecific antibodies. Dr. Budde points out that once T cells or CAR-T cells are fully activated, they become remarkably resistant to the immunosuppressive effects of steroids in both laboratory models and clinical practice, validating the safe use of steroids for toxicity management without compromising anti-tumor activity.

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies thumbnail

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies

Research To Practice | Oncology Videos·a month ago

CD20 Bispecifics Do Not Require Prophylactic Tocilizumab Unlike BCMA Myeloma Protocols

While prophylactic tocilizumab is standardly adopted to reduce CRS in multiple myeloma patients receiving BCMA-targeted bispecifics, it is unnecessary for CD20-targeted lymphoma bispecific antibodies. Due to differing tumor microenvironments and targets, CD20 bispecifics carry a distinct toxicity profile where routine tocilizumab prophylaxis provides no demonstrable clinical need, reserving the IL-6 inhibitor strictly for grade 2 or higher CRS.

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies thumbnail

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies

Research To Practice | Oncology Videos·a month ago

Prolonged Bispecific Therapy Requires Mandatory VZV and PJP Antimicrobial Prophylaxis

Because bispecific antibody regimens are administered over numerous cycles (8 to 12 cycles or more), normal B cells are continually suppressed and cannot recover. This induces severe, persistent hypogammaglobulinemia. All patients receiving B-cell bispecifics require acyclovir prophylaxis for shingles, PJP prophylaxis if receiving steroids, and regular IVIG replacement therapy to avoid chronic sinus and upper respiratory tract infections.

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies thumbnail

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies

Research To Practice | Oncology Videos·a month ago

Bispecific Combinations Effectively Debulk High-Burden Lymphoma as a Bridge to CAR-T

Rather than viewing bispecific antibodies and CAR-T cell therapy as mutually exclusive, Dr. Budde uses bispecific combinations as an off-the-shelf bridging strategy. High tumor burden and refractory disease reduce CAR-T response rates; administering an initial truncated course of bispecific combinations debulks aggressive lymphoma into deep remissions before transitioning patients to single-infusion CAR-T to complete treatment.

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies thumbnail

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies

Research To Practice | Oncology Videos·a month ago

Hold Granulocyte Colony-Stimulating Factor During Active Cytokine Release Syndrome to Prevent Confounded Diagnostics

Granulocyte colony-stimulating factor (G-CSF) should be temporarily withheld in patients experiencing unresolved cytokine release syndrome. G-CSF administration can independently trigger low-grade fevers and acute inflammatory symptoms, obscuring whether the patient's presentation is an escalating immune toxicity, infection, or standard drug side effect.

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies thumbnail

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies

Research To Practice | Oncology Videos·a month ago

Administer Polatuzumab Before Mosunetuzumab to Clear Circulating B Cells and Prevent CRS

When utilizing the combination of polatuzumab vedotin and mosunetuzumab in aggressive lymphoma, sequencing matters. Giving polatuzumab vedotin first depletes circulating B cells prior to bispecific antibody exposure. Dr. Budde notes that debulking tumor burden and clearing circulating target cells in this manner significantly lowers the subsequent incidence and severity of cytokine release syndrome.

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies thumbnail

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies

Research To Practice | Oncology Videos·a month ago

Bispecific Grade 1 CRS Requires Only Outpatient Antipyretics Unlike Escalating CAR-T Toxicity

Clinicians often conflate bispecific cytokine release syndrome with CAR-T CRS, creating undue reluctance in community settings. Bispecific grade 1 CRS typically presents with mild fevers (around 101°F) that rarely escalate into high-grade fevers (103°F–104°F) seen in CAR-T. In most cases, bispecific grade 1 CRS is safely controlled in the outpatient setting with acetaminophen, ibuprofen, or a single dose of oral dexamethasone.

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies thumbnail

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies

Research To Practice | Oncology Videos·a month ago